ABSTRACT: Benzothiazinones (BTZs) are antituberculosis drug candidates with nanomolar bactericidal activity against tubercle bacilli. Here we demonstrate that BTZs are suicide substrates of the FAD-dependent decaprenylphosphoryl-β-D-ribofuranose 2′-oxidase DprE1, an enzyme involved in cell-wall biogenesis. BTZs are reduced by DprE1 to an electrophile, which then reacts in a nearquantitative manner with an active-site cysteine of DprE1, thus providing a rationale for the extraordinary potency of BTZs. Mutant DprE1 enzymes from BTZ-resistant strains reduce BTZs to inert metabolites while avoiding covalent inactivation. Our results explain the basis for drug sensitivity and resistance to an exceptionally potent class of antituberculosis agents.
T he increasing number of drug-resistant Mycobacterium tuberculosis strains that fail to respond to first-and secondline drug treatment demands the development of new antituberculosis drugs.
1−3 Benzothiazinones (BTZs) such as BTZ043 ( Figure 1A ) are a promising class of new compounds that kill M. tuberculosis in vitro, ex vivo, and in mouse models of tuberculosis. 4 The minimal inhibitory concentration (MIC) of BTZ043 against M. tuberculosis is 1 ng/mL, which is significantly lower than the MICs of all currently used tuberculosis drugs and drug candidates. Decaprenylphosphoryl-β-D-ribofuranose 2′-epimerase was identified as a BTZ target ( Figure 1B) . 4 The enzyme is constituted of DprE1 and DprE2 that together catalyze the epimerization of decaprenylphosphoryl-β-D-ribofuranose (DPR) to decaprenylphosphoryl-β-Darabinofuranose (DPA), the arabinosyl donor for the biosynthesis of mycobacterial cell wall arabinan polymers. 4−6 The reaction is believed to proceed via the keto intermediate decaprenylphosphoryl-D-2′-keto-erythro-pentofuranose (DPX) ( Figure 1B) . 5 The Cys387Gly and Cys387Ser point mutations in DprE1 result in 250-and 10 000-fold increases in the MIC, respectively. 4 We previously isolated a covalent adduct of DprE1 and BTZ043 from mycobacteria incubated with BTZ043 and proposed a mechanism of action involving reduction of the essential nitro group of BTZ043 to a nitroso group that then reacts with Cys387 of DprE1 to form a stable semimercaptal ( Figure 1A ). 7 However, the mechanism of action of BTZs still poses numerous questions, as it is unclear how BTZs are activated and what the basis of the specificity of the proposed nitroso derivative for DprE1 is. Furthermore, it has not been elucidated whether the observed modification of DprE1 indeed affects the activity of DprE1 or functions by inhibiting the activity of DprE2 (or both); neither have the exact roles of DprE1 and DprE2 in the epimerization reaction been validated.
A more detailed characterization of the mechanism of action of BTZs requires the availability of pure DprE1 and DprE2. As our previous attempts to purify recombinant DprE1 and DprE2 of M. tuberculosis H37Rv in their active form were unsuccessful, Figure  S1A ,B in the Supporting Information (SI)].
Furthermore, mutation of Cys394 in DprE1 SM (corresponding to Cys387 in DprE1 of M. tuberculosis H37Rv) results in resistance of M. smegmatis toward BTZs. DprE1 SM and DprE2 SM were expressed in E. coli and purified to >95% homogeneity ( Figure S1C,D) . DprE1 SM was isolated to ∼45% with bound flavin adenine dinucleotide (FAD), confirming its annotation as a FAD-dependent oxidoreductase ( Figure S2 ). The activity of the purified DprE1 SM and DprE2 SM was confirmed by epimerization of decaprenylphosphoryl- . These data suggest that BTZs target DprE1 without affecting the activity of DprE2 SM and that DprE1 SM is responsible for the activation of the drug.
The difficulties in producing sufficient amounts of 14 C-DPR as well as its analysis precluded its use in more detailed mechanistic studies. We found that farnesylphosphoryl-β-Dribofuranose (FPR), which can be readily synthesized in greater quantities (see the SI), is an alternative substrate that is also epimerized by DprE1 SM and DprE2 SM ( Figure S3C Figure S3D ). The data lend further support to an epimerization mechanism in which DprE1 SM , using FAD as a cofactor, independently oxidizes FPR or DPR to the corresponding D-2′-keto-erythropentose, which is then reduced by DprE2 SM to FPA or DPA using NADH ( Figure 2B ).
For the detection of the proposed covalent BTZ−DprE1 adduct, we synthesized a fluorescently labeled BTZ derivative, BTZ-BODIPY-X ( Figure 2C ) (see the SI). Only weak fluorescent labeling of DprE1 SM was observed upon incubation of DprE1 SM with BTZ-BODIPY-X at 10 μM ( Figure 2C, lane 2) . However, the efficiency of the fluorescent labeling was increased about 8-fold upon addition of the DprE1 SM substrate FPR to the reaction mixture ( Figure 2D, lane 1) . Furthermore, fluorescent labeling could be suppressed or reversed by (i) heat inactivation of DprE1 SM , (ii) prior incubation with BTZ043, or (iii) subsequent incubation with an excess of thiols under denaturing conditions ( Figure 2D, lanes 3−5) . Together, thesedata suggest that DprE1 SM is capable of reducing BTZ-BODIPY-X to the corresponding electrophilic nitroso derivative, which then specifically reacts with DprE1 SM to form a covalent complex. We assume that reduction of the nitro group of BTZ-BODIPY to the nitroso derivative requires the presence of FADH 2 . This then explains the dependence of the labeling on the presence of FPR, which is needed to generate FADH 2 . There is literature precedent for the reduction of nitro groups by FAD-dependent enzymes: bacterial oxygen-insensitive nitroreductases such as NfsA and NfsB from E. coli and NfnB from M. smegmatis use flavin as redox cofactor for the reduction of nitroaromatic compounds.
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The reversal of the labeling by incubation of denatured, labeled DprE1 SM with excess thiols is in agreement with the formation of a semimercaptal from the nitroso derivative of Figure S4) .
To confirm the proposed formation of a semimercaptal between BTZ043 and DprE1 SM , we analyzed the covalent complex by MS. Analysis of the covalent drug−protein complex required its isolation under nonreducing conditions, and we showed previously that its MS analysis is facilitated by mutation of a second, nonessential cysteine residue, Cys136, to glycine in DprE1 SM ( G136 DprE1 SM ).
G136
DprE1 SM was incubated with BTZ043 as well as FPR and after buffer exchange subjected to MS analysis. We detected a protein with a mass of 51 656 Da, which corresponds to the mass of 51 657 Da expected for the semimercaptal adduct, as well as unmodified G136 DprE1 SM ( Figure 3A ). On the basis of peak intensities, the ratio of labeled G136 DprE1 SM to unlabeled G136 DprE1 SM was 3.5:1.
The incubation of semimercaptals with an excess of thiols is known to yield the corresponding hydroxylamines and amines. 11 We therefore analyzed the products resulting from incubation of the covalent BTZ043−DprE1 SM complex with an excess of thiols. In agreement with the proposed formation of a semimercaptal between BTZ043 and DprE1 SM , we detected the hydroxylamine and amine metabolites of BTZ043 in a ratio of 1.2:1 ( Figure S5B) . Furthermore, ∼0.72 equiv of BTZ metabolites was detected per molecule of DprE1 SM ( Figure S5B ).
The DprE1 SM mutations Cys394Gly and Cys394Ser result in resistance of M. smegmatis toward BTZ043, 4 and G394 DprE1 SM is not modified by BTZ043 ( Figure 2D ). We therefore speculated that Figure 3B ). For both mutants, no significant amounts of reduction products were detected in the absence of FPR ( Figure S6 ). Furthermore, wild-type DprE1 SM yielded no significant amount of either the amine or hydroxylamine under these conditions ( Figure 3B ). This indicates that the suicide inhibition of DprE1 SM is highly efficient. A possible explanation for the observed difference between the product ratios for G394 DprE1 SM and S394 DprE1 SM might be attributable to mutations of the active-site residue Cys394 that affect the substrate specificity of DprE1 SM .
In summary, we have reported on the characterization of DprE1 SM and DprE2 SM from M. smegmatis, key enzymes for cell-wall biogenesis, and the inactivation of DprE1 SM by BTZ043. The high degree of sequence identity of DprE1 SM and DprE2 SM with the orthologous proteins from M. tuberculosis and the fact that the same DprE1 mutations render both bacteria resistant to BTZs indicate that the mechanism of action of BTZs is identical in these two cases. To the best of our knowledge, BTZs represent the first example of suicide substrates that are activated through reduction of a nitro group (Figure 4) . It is noteworthy that the trapping of the nitroso derivative by the active-site residue of DprE1 SM occurs in a near-quantitative manner, providing a rationale for the extremely low MIC of BTZ043. Our data thus provide detailed insights into the mechanisms of BTZ sensitivity and resistance and represent an important step in the development of BTZs as tuberculosis drugs. 
